Tag: stage

HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- This press release has been updated to reflect the correct timing of the funding round.

REDWOOD CITY, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof) and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock (or pre-funded warrants in lieu thereof). In addition, Biomea intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock and pre-funded warrants offered in the public offering. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by Biomea.

– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development –

CONSHOHOCKEN, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on June 15, 2025 to 36 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2023 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- In a powerful show of support for America’s veterans, leading Diagnostic Radiologist Dr. Andrew Gomes has announced the creation of the Dr. Andrew Gomes Scholarship for Veterans, a new opportunity aimed at empowering those who have served in the military and are now pursuing undergraduate degrees. The scholarship, which is awarded through an essay-based application process, is now accepting submissions through March 15, 2026. The winning recipient will be announced on April 15, 2026.

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases.

Ingredient & Formulation Trade Show & Conference Solidifies Its Position as the Premier Event for Beauty & Personal Care Product Development